TSTsunehisa Sato

Tsunehisa Sato

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tsunehisa Sato has a total of 46 co-authors. Here are the top co-authors by number of shared publications:

  • Mutsuhito Kikura

    Department of Anesthesiology, Hamamatsu Rosai Hospital, Japan Organization of Occupational Health and Safety, Hamamatsu, Japan

    6 shared publications
  • Shingo Kawashima

    Department of Anesthesiology and Intensive Care, Hamamatsu University School of Medicine, Hamamatsu, Japan

    5 shared publications
  • Soichiro Mimuro

    Department of Anesthesiology and Intensive Care Medicine, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan

    3 shared publications
  • Takasumi Katoh

    Department of Anesthesiology and Intensive Care, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu, 431-3192, Japan

    3 shared publications
  • Yoshiki Nakajima

    浜松医科大学麻酔・蘇生学講

    3 shared publications
  • Yuji Suzuki

    Department of Anesthesiology and Intensive Care, Hamamatsu University School of Medicine, Hamamatsu, Japan

    3 shared publications

Latest Publications

  • Open Access

    The Role of Uncoupling Protein 2 in Renal Adaptation to Hypertension: Mechanistic Insights

    by Julia Sperhake, Rolf Schreckenberg, Tsunehisa Sato, Klaus-Dieter Schlüter

    Background/Objectives: Hypertension leads to chronic kidney disease, and downregulation of mitochondrial uncoupling protein 2 (UCP2) is part of this process. Using UCP2 knockout rats and L-NAME-induced hypertension may identify potential mechanistic insights that couple UCP2 downregulation with renal dysfunction. Methods: L-NAME induced hypertension maintained for four weeks in wild-type (WT) and UCP2-depleted rats (KO). Renal function was analyzed by blood urea nitrogen concentration, urinary albumin–creatinine ratio, and urine concentration of the tubule disease marker kidney injury molecule 1 (KIM-1). The expression of genes linked to carbohydrate and fatty acid metabolism, components of the renin–angiotensin system, or oxidative stress were analyzed by qRT-PCR. Key findings were confirmed by Western blot. Oxidative stress was analyzed by dihydroethidium staining. Results: In WT and KO rats, L-NAME induced a moderate increase in urine albumin–creatinine ratio and BUN concentration. In KO rats, it also increased the urine concentration of KIM1 and expression of Havcr, the gene coding for KIM1. In KO rats, renal expression of pyruvate dehydrogenase was reduced at mRNA and protein level. L-NAME induced the expression of angiotensin receptor type 1 in both strains, but increased the expression of Ren only in KO rats. All adaptations were tissue-specific. Conclusions: Downregulation of UCP2 accelerates the progression of tubule damage under hypertensive conditions. This effect is linked to metabolic effects shifting oxidative phosphorylation in mitochondria to oxidative glycolysis in the cytosol and furthermore by affecting the expression of genes linked to the local renin–angiotensin system.

  • Open Access

    Uncoupling Protein 2 and Nitric Oxide Deficiency Favor Glycolytic Pathways and Organ Growth in the Rat Spleen

    by Lea Wagner, Rolf Schreckenberg, Nadja Itani, Tsuneshiro Sato, Julia Sperhake, Yva Cesar, Klaus-Dieter Schlüter

    Uncoupling protein 2 (UCP2) is expressed in various tissues throughout the body, but its expression in the spleen exceeds that of other organs. However, the precise function of UCP2 for spleen physiology is unclear. The spleen acts as a hub connecting the nervous system and immune system to cardiovascular and metabolic diseases. Here, we analyzed the impact of hypertension on the spleen and the role of UCP2 in this process. Experiments were performed with UCP2-knockout rats and their wild-type littermates. Hypertension was induced by administering the nitric oxide inhibitor L-NAME via tap water. Genetic depletion of UCP2 increased spleen size (splenomegaly) and strongly impaired the expression of genes coding for mitochondrial proteins. Among them, genes coding for proteins involved in oxidative metabolism, such as pyruvate dehydrogenase alpha 1, and the detoxification of reactive oxygen species were down-regulated. Collectively, these alterations in metabolism favor glycolysis and proliferation. Moreover, NOS3 was among the strongest down-regulated genes in UCP2−/− rats, and the inhibition of nitric oxide synthase by L-NAME mimicked large parts of the expression profile. Neither the depletion of UCP2 nor L-NAME-induced hypertension or combinations thereof affected chronic inflammation. In summary, UCP2 controls fuel consumption in splenic cells in a nitric-oxide-dependent way.

  • Open Access

    Hydrogen attenuates endothelial glycocalyx damage associated with partial cardiopulmonary bypass in rats

    by Hiroki Iwata, Takasumi Katoh, Sang Kien Truong, Tsunehisa Sato, Shingo Kawashima, Soichiro Mimuro, Yoshiki Nakajima

    Cardiopulmonary bypass (CPB) causes systemic inflammation and endothelial glycocalyx damage. Hydrogen has anti-oxidant and anti-inflammatory properties; therefore, we hypothesized that hydrogen would alleviate endothelial glycocalyx damage caused by CPB. Twenty-eight male Sprague–Dawley rats were randomly divided into four groups (n = 7 per group), as follows: sham, control, 2% hydrogen, and 4% hydrogen. The rats were subjected to 90 minutes of partial CPB followed by 120 minutes of observation. In the hydrogen groups, hydrogen was administered via the ventilator and artificial lung during CPB, and via the ventilator for 60 minutes after CPB. After observation, blood collection, lung extraction, and perfusion fixation were performed, and the heart, lung, and brain endothelial glycocalyx thickness was measured by electron microscopy. The serum syndecan-1 concentration, a glycocalyx component, in the 4% hydrogen group (5.7 ± 4.4 pg/mL) was lower than in the control (19.5 ± 6.6 pg/mL) and 2% hydrogen (19.8 ± 5.0 pg/mL) groups (P < 0.001 for each), but it was not significantly different from the sham group (6.2 ± 4.0 pg/mL, P = 0.999). The endothelial glycocalyces of the heart and lung in the 4% hydrogen group were thicker than in the control group. The 4% hydrogen group had lower inflammatory cytokine concentrations (interleukin-1β and tumor necrosis factor-α) in serum and lung tissue, as well as a lower serum malondialdehyde concentration, than the control group. The 2% hydrogen group showed no significant difference in the serum syndecan-1 concentration compared with the control group. However, non-significant decreases in serum and lung tissue inflammatory cytokine concentrations, as well as in serum malondialdehyde concentration, were observed. Administration of 4% hydrogen via artificial and autologous lungs attenuated endothelial glycocalyx damage caused by partial CPB in rats, which might be mediated by the anti-inflammatory and anti-oxidant properties of hydrogen.


  • Open Access

    微小循環の生理~グリコカリックスと改訂Starlingの法則

    by Takuya Niwa, Tsunehisa Sato, Soichiro Mimuro, Yoshiki Nakajima

    1896年に提唱されたStarlingの法則は,毛細血管と間質の体液の移動を説明するものである.Starlingは,毛細血管内外の静水圧と浸透圧の差が体液の移動量を決定する要因であると述べた.しかし,この法則はグリコカリックスという新たな要素の発見によって再検討されることとなった.グリコカリックスは,血管内皮の内側を覆う糖蛋白質複合体であり,毛細血管と間質の体液の移動に重要な役割を果たしている.改訂されたStarlingの法則では,グリコカリックス直下の膠質浸透圧が重要であり,従来の法則よりも体液の間質への移動量は小さくなることが示された.また,動脈側から静脈側にかけての静水圧の変化や膠質浸透圧の影響が考慮され,血管内と間質の体液の移動が詳細に説明された.グリコカリックスが微小循環の生理において重要な役割を担っていることが明らかになってきた.また,グリコカリックスの役割は多岐にわたっており,さらなる研究の進展が期待されている.

  • 1.2% Hydrogen gas inhalation protects the endothelial glycocalyx during hemorrhagic shock: a prospective laboratory study in rats

    by Tsunehisa Sato, Soichiro Mimuro, Takasumi Katoh, Tadayoshi Kurita, Sang Kien Truong, Kensuke Kobayashi, Hiroshi Makino, Matsuyuki Doi, Yoshiki Nakajima

    Purpose Hydrogen gas (H2) inhalation improved the survival rate of hemorrhagic shock. However, its mechanisms are unknown. We hypothesized that H2 protected the endothelial glycocalyx during hemorrhagic shock and prolonged survival time. Methods 83 Sprague–Dawley rats were anesthetized with isoflurane. The animals were randomly assigned to 5 groups: room air with no shock, 1.2% H2 with no shock, room air with shock (Control-S), 1.2% H2 with shock (H21.2%-S), and 3.0% H2 with shock (H23.0%-S). Shock groups were bled to a mean arterial pressure of 30–35 mmHg and held for 60 min, then resuscitated with normal saline at fourfold the amount of the shed blood volume. Results The syndecan-1 level was significantly lower in the H21.2%-S [8.3 ± 6.6 ng/ml; P = 0.01; 95% confidence interval (CI), 3.2–35.8] than in the Control-S (27.9 ± 17.0 ng/ml). The endothelial glycocalyx was significantly thicker in the H21.2%-S (0.15 ± 0.02 µm; P = 0.007; 95% CI, 0.02–0.2) than in the Control-S (0.06 ± 0.02 µm). The survival time was longer in the H21.2%-S (327 ± 67 min, P = 0.0160) than in the Control-S (246 ± 69 min). The hemoglobin level was significantly lower in the H21.2%-S (9.4 ± 0.5 g/dl; P = 0.0034; 95% CI, 0.6–2.9) than in the Control-S (11.1 ± 0.8 g/dl). However, the H23.0%-S was not significant. Conclusions Inhalation of 1.2% H2 gas protected the endothelial glycocalyx and prolonged survival time during hemorrhagic shock. Therapeutic efficacy might vary depending on the concentration.


  • Dexmedetomidine preserves the endothelial glycocalyx and improves survival in a rat heatstroke model

    by Kensuke Kobayashi, Soichiro Mimuro, Tsunehisa Sato, Atsushi Kobayashi, Shingo Kawashima, Hiroshi Makino, Matsuyuki Doi, Takasumi Katoh, Yoshiki Nakajima

    Heatstroke causes systemic inflammation, followed by vascular endothelial damage. The normal vascular endothelium is coated by endothelial glycocalyx (EGCX). Dexmedetomidine (DEX) has an anti-inflammatory effect, but there has been little investigation on the influence of heatstroke on EGCX and the effect of DEX on this condition. Therefore, we examined whether EGCX was disrupted in heatstroke and if DEX improved survival and preserves EGCX.


  • Open Access

    Four-Group Classification Based on Fibrinogen Level and Fibrin Polymerization Associated With Postoperative Bleeding in Cardiac Surgery

    by Shingo Kawashima, Yuji Suzuki, Tsunehisa Sato, Mutsuhito Kikura, Takasumi Katoh, Shigehito Sato

    Fibrinogen and fibrin formation have a key role in perioperative hemostasis. The aim of this study is to examine the association of postoperative hemostasis with a combined evaluation of the fibrinogen level and fibrin polymerization in cardiac surgery. We retrospectively classified 215 consecutive cardiac surgery patients into 4 groups (Fuji-san classification) that were divided by fibrinogen level P < .01) and group III (OR, 8.5; 95% CI, 3.5-21.7; P < .01), and the risk greater than 1000 mL (with group I as the reference) was increased in group III (OR, 4.0; 95% CI, 1.1-17.3; P = .03) and group IV (OR, 23.1; 95% CI, 3.2-201.0; P < .01). Intraoperative blood transfusions were decreased by 24.5%, after stratifying the starting amount of fresh frozen plasma by the 4-group classification in the recent consecutive 65 (30.2%) patients (P < .01). The 4-group classification is associated with postoperative bleeding and may improve the quality of perioperative blood transfusion in cardiac surgery.


    • 1 June 2016
      • Vol. 65  (6) , 566-72

    [Assessment of Fibrinogen Replacement Therapy by the Combined Simulation of the Fibrinogen Concentration and Fibrin Polymerization].

    by Yuji Suzuki, Shingo Kawashima, Tsunehisa Sato, Junko Nishino, Mutsuhito Kikura

    Fibrinogen replacement therapy is effective for attaining perioperative hemostasis in critical bleeding due to acquired hypofibrinogenemia. By simulating the fibrinogen level and fibrin polymerization, we compared the effect of fibrinogen replacement therapy using cryoprecipitate or fibrinogen concentrate versus the effect of fresh frozen plasma. We simulated the plasma concentration of fibrinogen during fibrinogen replacement therapy in a model of cardiopulmonary bypass (CPB) and intensive care unit (ICU). We estimated fibrin polymerization (FIBTEM A10, thromboelastometry) by the simulated fibrinogen level, and compared this value with the fibrinogen level and FIBTEM in clinical patients. In the simulation model of CPB and ICU, cryoprecipitate and fibrinogen concentrate both effectively restored the fibrinogen level and FIBTEM, compared to fresh frozen plasma. In clinical patients, the simulated values of the fibrinogen level and FIBTEM after administering the fibrinogen concentrate were similar to the measured values. In the simulation model, which combines the fibrinogen level and fibrin polymerization, cryoprecipitate and fibrinogen concentrate effectively normalize the fibrinogen level and fibrin polymerization, compared to fresh frozen plasma. The fibrinogen concentrate also demonstrated efficacy in treating hypofibrinogenemia in clinical patients. The combined simulation model is useful in assessing the efficacy of fibrinogen replacement therapy by cryoprecipitate or by fibrinogen concentrate.

    • 1 January 2015
      • Vol. 64  (1) , 57-9

    [Vocal cord paralysis associated with tracheal intubation: incidence, risk analysis, and classification of severity].

    by Mutsuhito Kikura, Yuji Suzuki, Taiga Itagaki, Tsunehisa Sato, Junko Nishino

    Vocal cord paralysis after tracheal intubation is rare. It causes severe hoarseness and aspiration, and delays recovery and discharge. Arytenoid cartilage dislocation and recurrent nerve paralysis are main causes of vocal cord paralysis. Physical stimulation of the tracheal tube as well as patient and surgical characteristics also contribute. Vocal cord paralysis occurs in 1 (0.07%) of 1,500 general surgery patients and on the left side in 70% of cases. It is associated with surgery/anesthesia time (two-fold, 3-6 hours; 15-fold, over 6 hours), age (three-fold, over 50 years), and diabetes mellitus or hypertension (two-fold). Symptoms resolve in 2-3 months. In adult cardiovascular surgery, vocal cord paralysis occurs in 1 (0.7-2%) of 50-100 cardiac surgery patients and 1 (8.6-32%) of 3-10 thoracic aortic surgery patients. In pediatric cardiac surgery, vocal cord paralysis occurs in 1 (0.1-0.5%) of 200-1,000 patients. We classified the severity of vocal cord paralysis as I, severe hoarseness; II, aspiration or dysphagia; and III, bilateral vocal cord paralysis, aspiration pneumonia, or the need for tracheal re-intubation or tracheotomy. We discuss the importance of informed consent for the patient and family.